Curanex Pharmaceuticals Inc Common Stock
CURXHealthcare|Biotechnology|US
$6.21
+0.43 (+7.44%)
DCF Value
$3.26
Tangible Book / Share
$3.38
Cash / Share
$2.07
Financials
Financial Snapshot
Market Cap
$9.7M
Enterprise Value
$7.1M
Revenue (TTM)
$0.00
Net Income (TTM)
-$10.5M
Cash & Investments
$2.9M
Net Cash
$2.7M
Free Cash Flow (TTM)
-$12.1M
Operating CF (TTM)
-$12.1M
Debt/Equity
0.06
Cash Runway & Burn Rate
Cash on Hand
$2.9M
Quarterly Burn
$3.0M
Monthly Burn
$1.0M
Est. Runway
~1.0 quarters
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Investments | — | $74.4K | $148.9K | $5.0M | $2.9M | |
| Operating Cash Flow | — | -$120.00 | -$555.6K | -$10.5M | -$12.1M | |
| Free Cash Flow | — | -$120.00 | -$555.6K | -$10.5M | -$12.1M | |
| Capital Expenditure | — | $0.00 | $5.00 | $0.00 | $0.00 | |
| Financing Cash Flow | — | $72.1K | $630.1K | $15.3M | $14.9M |
R&D Spending
R&D (TTM)
$7.8M
R&D Intensity
—
R&D Growth vs Prior
+162.4%
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $26.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $0.00 | $0.00 | $3.0M | $7.8M | |
| R&D % of Revenue | 0.0% | — | — | — | — | |
| SG&A | $24.7K | $19.3K | $290.4K | $1.3M | $2.7M |
Income Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $26.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $21.6K | $0.00 | $0.00 | $0.00 | $69.3K | |
| Gross Profit | $4.4K | $0.00 | $0.00 | $0.00 | -$69.3K | |
| R&D | $0.00 | $0.00 | $0.00 | $3.0M | $7.8M | |
| SG&A | $24.7K | $19.3K | $290.4K | $1.3M | $2.7M | |
| Operating Income | -$20.2K | -$19.3K | -$365.1K | -$4.2M | -$10.6M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $8.5K | $4.1K | |
| Pretax Income | -$20.2K | -$19.2K | -$361.5K | -$4.2M | -$10.5M | |
| Net Income | -$20.2K | -$19.2K | -$361.5K | -$4.2M | -$10.5M | |
| EPS (Diluted) | -0.01 | -0.01 | -0.26 | -2.98 | -7.38 | |
| EBITDA | $925.00 | -$17.5K | -$290.4K | -$4.1M | -$10.4M | |
| Shares Out. (M) | 1.39 | 1.39 | 1.39 | 1.42 | 1.42 |
Balance Sheet
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Equivalents | — | $74.4K | $148.9K | $5.0M | $2.9M | |
| Short-Term Investments | — | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | — | $74.4K | $517.9K | $11.2M | $4.8M | |
| Total Assets | — | $74.4K | $517.9K | $11.6M | $5.1M | |
| Total Current Liabilities | — | $14.3K | $14.6K | $137.0K | $104.3K | |
| Long-Term Debt | — | $0.00 | $0.00 | $224.0K | $181.9K | |
| Total Liabilities | — | $14.3K | $14.6K | $361.0K | $286.3K | |
| Stockholders' Equity | — | $60.1K | $503.4K | $11.2M | $4.8M | |
| Retained Earnings | — | -$260.9K | -$622.4K | -$4.8M | -$11.3M |
Cash Flow Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Operating Cash Flow | — | -$120.00 | -$555.6K | -$10.5M | -$12.1M | |
| Capital Expenditure | — | $0.00 | $5.00 | $0.00 | $0.00 | |
| Free Cash Flow | — | -$120.00 | -$555.6K | -$10.5M | -$12.1M | |
| Investing Cash Flow | — | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | — | $72.1K | $630.1K | $15.3M | $14.9M | |
| Issuance of Stock | — | $69.1K | $630.0K | $15.7M | $15.7M | |
| Repurchase of Stock | — | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | — | $0.00 | $0.00 | $0.00 | -$400.0K | |
| Stock Based Comp. | — | $0.00 | $0.00 | $0.00 | $9.8K | |
| Net Change in Cash | — | $71.9K | $74.5K | $4.8M | $2.8M |
Dilution Tracker
Shares Outstanding
2M
5-Year Share Growth
+2.1%
Stock Issuance (TTM)
$15.7M
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.39 | 1.39 | 1.39 | 1.42 | 1.42 | |
| Change vs Prior % | — | 0.0% | 0.0% | 2.1% | 0.1% | |
| Stock Issuance | — | $69.1K | $630.0K | $15.7M | $15.7M | |
| Stock Repurchase | — | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | — | $0.00 | $0.00 | $0.00 | $9.8K |
Margins & Profitability
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Gross Margin % | 17.0% | — | — | — | — | |
| Operating Margin % | -77.8% | — | — | — | — | |
| Net Margin % | -77.8% | — | — | — | — | |
| EBITDA Margin % | 3.6% | — | — | — | — | |
| ROE % | 0.0% | -31.9% | -71.8% | -37.7% | -109.1% | |
| ROA % | 0.0% | -25.8% | -69.8% | -36.5% | -206.3% | |
| ROIC % | 0.0% | -32.1% | -72.5% | -36.7% | -208.4% | |
| R&D / Revenue % | 0.0% | — | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0.0% | -100.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -100.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | 4.6% | -1791.7% | -1061.2% | |
| Net Income | 0.0% | 5.1% | -1783.0% | -1068.8% | |
| EPS (Diluted) | 0.0% | 5.5% | -1784.1% | -1046.2% | |
| Operating Cash Flow | 0.0% | 0.0% | -462879.2% | -1787.1% | |
| Free Cash Flow | 0.0% | 0.0% | -462879.2% | -1787.1% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A Expense | 0.0% | -21.8% | 1404.7% | 331.6% | |
| Total Assets | 0.0% | 0.0% | 596.5% | 2135.8% | |
| Book Value / Share | 0.0% | 0.0% | 737.7% | 2082.4% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 2.1% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B1.84
10Y Low / Med / High0.83 / 221.62 / 1856.47
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$3.26
Tangible Book / Share
$3.38
Net Current Assets / Share
$2.87
Graham Net-Net
$1.87
Cash / Share
$2.07
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| P/E Ratio | -5506.85 | -5826.09 | -309.23 | -2.22 | -0.84 | |
| P/S Ratio | 4290.58 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.00 | 1856.47 | 221.62 | 0.83 | 1.84 | |
| EV/EBITDA | 0.00 | -6376.52 | -383.65 | -1.15 | -0.68 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
11.57
Safe
Piotroski F-Score
2
Weak